Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gazyva in Relapsed/Refractory PTLD
NCT03086395Phase 2Withdrawn
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of obinutuzumab in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Case Comprehensive Cancer Center. Planned start Apr 2017; status: withdrawn.
02
Drugs
obinutuzumab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT03086395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086395.